• Slide
  • Slide
  • Slide

Briggs Morrison, MD - Chairman of Cerenis’ SAB Oncology
Former Head of Global Medicines Development and Chief Medical Officer at AstraZeneca

Briggs W. Morrison received his B.S. in biology from Georgetown University, his M.D. from the University of Connecticut Medical School, completed residency training in Internal Medicine at the Massachusetts General Hospital, and completed a fellowship in Medical Oncology at the Dana-Farber Cancer Institute. He did post-docs with Dr. Philip Leder at Harvard Medical School, and Dr. Lee Nadler at the Dana-Farber Cancer Institute. He joined Merck & Co., Inc. in 1995, where he held various R+D positions including leading the Clinical Oncology Department. Subsequently he was appointed Head of Clinical Development at Pfizer in 2007, and became the Head of Global Medicines Development and Chief Medical Officer at AstraZeneca in 2012. He is currently the CEO of Syndax Pharmaceuticals. Dr. Morrison has overseen the development of numerous biopharmaceutical products in multiple therapeutic areas, from First-In-Human trials through to global regulatory approvals. He is currently a Board member of private companies Oncorus and Repare Therapeutics, and is an advisor to a number of other private biotechnology companies. In addition, Dr. Morrison is a Board member of the Alliance for Clinical Research Excellence and Safety (ACRES), a non-profit organization dedicated to optimizing the global clinical research system.

Mark Frohlich, MD
Former Executive V.P. of Portfolio Strategy at Juno Therapeutics

Dr. Mark Frohlich has been involved in the development of cellular immunotherapies for cancer for more than 15 years. He was recently EVP of Portfolio Strategy at Juno Therapeutics, prior to its $9 billion acquisition by Celgene. He previously served as EVP of R&D and Chief Medical Officer of Dendreon Corporation, where he led the clinical team responsible for the approval of the first cellular immunotherapy in the US and Europe (Provenge®). Prior to that he led the clinical team at Xcyte Therapies, developing autologous activated T cells for cancer. Dr. Frohlich is a medical oncologist. He is a graduate of Harvard Medical School and Yale College.

Aurélien Marabelle, MD, PhD
Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy Cancer Center

Dr. Aurélien Marabelle's clinical practice is dedicated to early phase clinical trials in Cancer Immunotherapy. His translational research is focused on mechanisms of action of immune checkpoint monoclonal antibodies. He works as a senior medical oncologist and an investigator in the Drug Development Department (DITEP) directed by Dr. Christophe Massard. He is coordinating a team focusing on cancer immunotherapy translational research projects in the INSERM U1015 lab directed by Prof Laurence Zitvogel. Dr. Marabelle is a member of ESMO, ASCO, EATI and AACR.

Robert Schneider, PhD
Albert Sabin Professor of Molecular Pathogenesis, Professor of Radiation Oncology

Dr. Robert Schneider is associate Director of the NYU Cancer Institute, Director of Translational Cancer Research, and Co-director of the Breast Cancer Research Program at NYU School of Medicine. He is also the Associate Dean for NYU Technology Ventures and Partnerships, which has transformed NYU’s technology transfer and commercialization into a leading therapeutics development and new company academic enterprise. Dr. Schneider is also an active researcher, and performs basic, translational, and clinical research on the molecular basis of metastatic breast and ovarian cancers, interconnections with the inflammatory response, and the development of new therapeutics. He is the author of more than 160 peer-reviewed publications. He has received a number of awards in recognition for his achievements, including the 2012 Susan E. Donelan Hope for the Future Award for breast cancer research from the Dana Farber Cancer Institute; the 2011 Distinguished Alumnus Award & Commencement address from the University of Delaware; the 2010 Judah Folkman Memorial lecture from the Chemotherapy Society, among others. Dr. Schneider is a co-founding scientist of six biotechnology/small pharmaceutical companies including ImClone Systems (New York), PTC Therapeutics (New Jersey), Canji (San Diego), Gencell (Paris) and ENB Therapeutics (New York). Dr. Schneider received his Ph.D. in biomedical sciences from the Mount Sinai School of Medicine and was a postdoctoral research fellow in the Department of Molecular Biology at Princeton University.

Robert Spiegel, MD
Former Sr. V.P. for worldwide Clinical Research and Chief Medical Officer at Schering-Plough

Dr. Spiegel has over 30 years of extensive R&D and operational experience in biopharmaceuticals including Big Pharma, biotech, and academic startups as well as interactions advising venture capital and private equity. Dr. Spiegel spent over 25 years at Schering-Plough where he joined as the first Director for Oncology Clinical Research, and subsequently held a series of senior executive positions, including Senior Vice President for worldwide Clinical Research and Chief Medical Officer. During his time at Schering-Plough he took numerous drug candidates through clinical development and was involved with over 30 NDA approvals at the FDA. For the last five years Dr. Spiegel has been a consultant to the biotech industry and has served on the Boards of multiple biotech companies He currently serves on the Boards of Directors of Geron Corp, Edge Therapeutics, and Neximmune Inc. and is Chairman of Vidac Therapeutics. He is currently the principal of Spiegel Consulting LLC and an Assistant Professor of Medicine at Weill Cornell Medical College. He is also a Senior Advisor to private equity firm Warburg Pincus and an Advisor to the Israel Biotech Fund. Dr. Spiegel received his B.A. from Yale University and his M.D. from the University of Pennsylvania. He completed his specialty training at the National Cancer Institute, National Institutes of Health (NIH).





Cerenis Therapeutics Holding SA
33-43 av. Georges Pompidou – Bât. D2
31130 Balma – France
Tel. +33 5 62 24 97 06
Fax +33 5 61 57 34 12

Email: info@cerenis.com

Cerenis Therapeutics Inc
PO Box 861
Lakeland, MI 48143